Cisplatin plus Radiotherapy in Bladder Cancer

Sauer, Rolf; Dunst, Jürgen

doi:10.1007/978-3-642-84186-6_25

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the series with concurrent chemo-radiation, after 40Gy plus Cisplatin, 44% of the patients in Innsbruck [16] and 65% in the RTOG protocol 85-12 [17] achieved a complete response, 70% of the patients In Erlangen have complete response after 50Gy plus Cisplatin [14]. In this study, 84% with complete response were observed with 60-70Gy.…”

Section: Bladder-preservation Therapy In Muscle-invasive Bladdermentioning

confidence: 49%

“…The series from preoperative regimens suggest that radiation doses of 40-50Gy will eradicate not more than 35% of all bladder tumors [14]. The best results have been obtained by EDSMYR et al, who have reported a 62% local control rate of T2-4 tumors at 6 months after hyperfractionated radiotherapy [15].…”

Section: Bladder-preservation Therapy In Muscle-invasive Bladdermentioning

confidence: 99%

See 1 more Smart Citation

Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Single Centre Experience

Bourhafour¹,

Elallam²,

Elalami³

et al. 2016

IOSR

View full text Add to dashboard Cite

(6%), 21 (46%), 7 (15%) and 15 (33%) for T1, T2, T3 and T4, respectively. Treatment consisted in a transurethral resection of bladder tumor as complete as feasible followed by curative concurrent chemoradiation. Results:Twenty-nine patients showed complete response (CR), 22 of whom (48%) had a continuously tumor free bladder. With a median follow-up of 30 months (12-92 months), the 3-year overall survival (OS) was 50%; Local recurrence-free survival (LRFS) was 59% at 3 years and the distant metastases free survival (MFS) was

show abstract

Section: Bladder-preservation Therapy In Muscle-invasive Bladdermentioning

confidence: 49%

Section: Bladder-preservation Therapy In Muscle-invasive Bladdermentioning

confidence: 99%